In the BioHarmony Drug Report Database

"Preview" Icon

Vorinostat

Zolinza (vorinostat) is a small molecule pharmaceutical. Vorinostat was first approved as Zolinza on 2006-10-06. It is used to treat t-cell lymphoma cutaneous in the USA. The pharmaceutical is active against histone deacetylase 1. In addition, it is known to target histone deacetylase 9, histone deacetylase 11, histone deacetylase 3, histone deacetylase 2, histone deacetylase 6, polyamine deacetylase HDAC10, histone deacetylase 5, and histone deacetylase 8. Zolinza’s patents are valid until 2028-03-18 (FDA).

 

Trade Name

 

Zolinza
 

Common Name

 

vorinostat
 

ChEMBL ID

 

CHEMBL98
 

Indication

 

t-cell lymphoma cutaneous
 

Drug Class

 

Enzyme inhibitors: inhibitors of histone deacetylase

Image (chem structure or protein)

Vorinostat structure rendering